Korro Bio, Inc. Share Price & Technical Analysis
KRRO · $11.61 (+3.66%)
Healthcare / Biotechnology
$11.61
+3.66%
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate d…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-13% return in May, -18% avg return in past 3 year May month.
59% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 64% | -8% | -2% | 18% | -13% | – | – | – | – | – | – | – | 59% |
| 25 | -13% | -25% | -31% | 4% | -36% | 8% | 20% | 55% | 111% | -14% | -86% | 45% | 39% |
| 24 | 8% | -5% | 89% | -36% | -7% | -33% | 38% | 4% | -29% | 73% | -12% | -28% | 63% |
| 23 | 14% | -85% | -27% | -22% | -10% | -1% | 55% | -4% | -24% | -35% | 235% | 14% | 108% |
| 22 | 5% | -48% | -25% | -39% | -15% | 34% | 28% | 4% | -13% | -2% | 28% | 73% | 31% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$157.21M
P/E ratio
—
52W high
$55.89
52W low
$5.20
Volume
2,31,218
Beta
2.23
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Korro Bio, Inc. share price today?
- Korro Bio, Inc. (KRRO) last traded around $11.61 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KRRO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KRRO. Download the app for real-time alerts.
- How can I analyze Korro Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.